<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Leap Therapeutics, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Leap Therapeutics, Inc.

    Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Chris Mirabelli, Ph.D.
    • FOUNDED
      2011
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Catasys, Inc.

    Catasys, Inc.

    Catasys has contracted with leading national, regional and local health insurance ...

    Catasys has contracted with leading national, r...

    Filing Type:    PU
    MiMedx Group, Inc.

    MiMedx Group, Inc.

    MiMedxŽ is a biopharmaceutical company developing, manufacturing and marketing reg...

    MiMedxŽ is a biopharmaceutical company developi...

    Filing Type:    PU
    Bioclonetics Immunotherapeutics, Inc.

    Bioclonetics Immunotherapeutics, Inc.

    BioClonetics Immunotherapeutics is a biotechnology company with a proprietary meth...

    BioClonetics Immunotherapeutics is a biotechnol...

    Amount Raised:    $255,600
    Fundraising Status:    EC
    Filing Type:    CF
    Marker Therapeutics, Inc.

    Marker Therapeutics, Inc.

    We are a clinical-stage immuno-oncology company specializing in the development an...

    We are a clinical-stage immuno-oncology company...

    Filing Type:    PU
    Aerie Pharmaceuticals, Inc.

    Aerie Pharmaceuticals, Inc.

    Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the disco...

    Aerie Pharmaceuticals is an ophthalmic pharmace...

    Filing Type:    PU
    Rigel Pharmaceuticals, Inc.

    Rigel Pharmaceuticals, Inc.

    Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, d...

    Rigel Pharmaceuticals, Inc. is a biotechnology ...

    Filing Type:    PU
    Personalis, Inc.

    Personalis, Inc.

    Personalis, Inc. is a growing cancer genomics company transforming the development...

    Personalis, Inc. is a growing cancer genomics c...

    Filing Type:    PU
    Oncolytics Biotech Inc.

    Oncolytics Biotech Inc.

    Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...

    Oncolytics is focused on obtaining regulatory a...

    Filing Type:    PU
    Sierra Oncology, Inc.

    Sierra Oncology, Inc.

    Sierra Oncology is a clinical stage drug development company advancing targeted th...

    Sierra Oncology is a clinical stage drug develo...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.